ArticleScientific reports2015
A streamlined search technology for identification of synergistic drug combinations.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 82 citations in OpenAlex.
- The role of nanomedicine and artificial intelligence in cancer health care: individual applications and emerging integrations-a narrative review.Discover oncology · 2025Review
- Article
- Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer.Cellular and molecular life sciences : CMLS · 2023Article
- Identifying mutant-specific multi-drug combinations using comparative network reconstruction.iScience · 2022Article
- Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma.Cancers · 2021Article
- Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering.Apoptosis : an international journal on programmed cell death · 2021Review
- Predicting the Effects of Drug Combinations Using Probabilistic Matrix Factorization.Frontiers in bioinformatics · 2021Article
- Synergistic Dose Permutation of Isolated Alkaloid and Sterol for Anticancer Effect on Young Swiss Albino Mice.Drug design, development and therapy · 2021Article
- Multiobjective optimization identifies cancer-selective combination therapies.PLoS computational biology · 2020Article
- Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment.Molecular oncology · 2020Article
- Article
- Article
- Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma.British journal of cancer · 2020Article
- Article
- Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment.Molecules (Basel, Switzerland) · 2020Article
- Article
- Cellular Signaling Analysis shows antiviral, ribavirin-mediated ribosomal signaling modulation.Antiviral research · 2019Article
- Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering.Cancers · 2019Article
- A nanodroplet cell processing platform facilitating drug synergy evaluations for anti-cancer treatments.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major key to improvement of cancer therapy is the combination of drugs. Mixing drugs that already exist on the market may offer an attractive alternative. Here we report on a new model-based streamlined feedback system control (s-FSC) method, based on a design of experiment approach, for rapidly finding optimal drug mixtures with minimal experimental effort. We tested combinations in an in vitro assay for the viability of a renal cell adenocarcinoma (RCC) cell line, 786-O. An iterative cycle of in vitro testing and s-FSC analysis was repeated a few times until an optimal low dose combination was reached. Starting with ten drugs that target parallel pathways known to play a role in the development and progression of RCC, we identified the best overall drug combination, being a mixture of four drugs (axitinib, erlotinib, dasatinib and AZD4547) at low doses, inhibiting 90% of cell viability. The removal of AZD4547 from the optimized drug combination resulted in 80% of cell viability inhibition, while still maintaining the synergistic interaction. These optimized drug combinations were significantly more potent than monotherapies of all individual drugs (p < 0.001, CI < 0.3).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.